Medicine Iontophoresis Market –
Regional Analysis
On the basis of region, the
global Medicine
Iontophoresis Market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
North America is projected to
hold dominant position in the global medicine iontophoresis market due to
insurance and reimbursement strategies for treating hyperhidrosis patients. For
instance, in the U.S., International Hyperhidrosis Society offers useful tools,
information, and downloadable forms related to the insurance and reimbursement
process. This comprises health plans for hyperhidrosis treatments, cost of
therapy, medical insurance form for purchasing iontophoresis devices, and
others. Such insurance and reimbursement services allow efficient treatment of
hyperhidrosis.
Iontophoresis is a technique,
which uses an electric current to deliver a medicine or other chemicals through
the skin. Iontophoresis is often suggested for people with hyperhidrosis
(excessive sweating) of the hands and/or feet as it aids in reducing sweating.
Iontophoresis is suitable for applications such as acetic acid (calcific
tendinitis), calcium chloride and magnesium sulfate (control of musculoskeletal
spasms), dexamethasone (inflammation), lidocaine (inflammation of soft
tissues), and zinc oxide (rheumatoid arthritis).
Medicine Iontophoresis Market
Drivers
Increasing awareness for
treatment of hyperhidrosis is expected to drive growth of the medicine
iontophoresis market. For instance, in the U.S., the International
Hyperhidrosis Society (IHhS) IHhS celebrates the month of November as
Hyperhidrosis Awareness Month by making documentaries, conducting interviews of
patients, and organizing various events to raise awareness of hyperhidrosis
among the populace.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2248
Moreover, increasing research on
iontophoresis in treating various diseases and symptoms is expected to boost
growth of the medicine iontophoresis market. For instance, in April 2018,
EyeGate Pharma Company developed a novel ocular drug delivery system called
EyeGate II iontophoresis, where an electric current generated in the device
delivers ionized drug into the eye and further gets absorbed into the eye by
the electric current.
Furthermore, approval for new
products for medicine iontophoresis therapy is expected to propel the medicine
iontophoresis market growth. For instance, in May 2017, Soterix Medical Inc.,
the U.S.-based firm, received a 510(k) clearance from the U.S. Food and Drug
Administration (U.S FDA), for its IontoDC device intended to use direct current
to introduce ions of soluble salts or other drugs in the body.
Medicine Iontophoresis Market
Restraints
Side effects and the limitations
associated with medicine iontophoresis therapy are expected to restrain
medicine iontophoresis market growth. For instance, according to British
Association of Dermatologists 2016 report, people often complain symptoms of
bruising or blisters incase the intensity of current is too high for
iontophoresis, a sensation of mild burning in case the electrode is touched,
and itchiness in the treated area after treatment. Moreover, patients with
cardiac pacemakers or with metal implants are not suitable for iontophoresis
treatment.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/medicine-iontophoresis-market-2248
Furthermore, product recalls due
to failure in meeting regulatory standards is expected to restrain growth of
the medicine iontophoresis market. For instance, in August 2016, Health Canada
recalled IONTODERMA ID-1000, a product of IONTODERMA, due to failure to comply
medical devices regulations and for selling medical devices without proper
license.
Furthermore, increasing research
and development activities to launch advanced iontophoresis devices for
treating ophthalmic diseases in Asia Pacific is expected to contribute to
substantial growth in the global medicine iontophoresis market. For instance,
in March 2018, annual meeting of Association for Research in Vision and
Ophthalmology (ARVO) 2018 was held in China where, Aciont Inc. opened up
clinical data for its lead product, Dexamethasone Sodium Phosphate (DSP)-Visulex.
DSP-Visulex is a non-invasive drug delivery system based on ocular
iontophoresis technique. This product can be used for the treatment of non-infectious
anterior uveitis.
Medicine Iontophoresis Market
Competitor Analysis
Key players operating in the
global medicine iontophoresis market include, ORGANIX GmbH & Co. KG, Hidrex
USA, Drionic, IOMED, R.A. Fischer, Iskra Medical d.o.o., Chattanooga, Encore
Medical, L.P., iTech Medical, Inc., Kimetec GmbH, and AAM.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2248
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment